Table 4.

Relationship between GPR126 mutation status and standard clinical, pathologic, and biological parameters in NMIBC

GPR126 mutatedGPR126 not mutated
Total population (%)N (%)N (%)Pa
Total population44 (100.0)21 (47.7)23 (52.3)
Age (years)
 ≥6034 (77.3)19 (55.9)15 (44.1)0.10
 <6010 (22.7)2 (20.0)8 (80.0)
Sex
 Male41 (93.2)18 (43.9)23 (56.1)0.10
 Female3 (6.8)3 (100.0)0 (0.0)
Smoking status
 Nonsmoker19 (43.2)13 (68.4)6 (31.6)0.017
 Smoker25 (56.8)8 (32.0)17 (68.0)
History of NMIBC
 No24 (54.5)7 (29.2)17 (70.8)0.0069
 Yes20 (45.5)14 (70.0)6 (30.0)
Associated pTis
 No42 (95.4)20 (47.6)22 (52.4)>0.99
 Yes2 (4.6)1 (50.0)1 (50.0)
Grade
 Low grade20 (45.5)8 (40.0)12 (60.0)0.35
 High grade24 (54.5)13 (54.2)11 (45.8)
Tumor stage
 Ta30 (68.2)14 (46.7)16 (53.3)0.84
 T114 (31.8)7 (50.0)7 (50.0)
FGFR3 status
 Mutated22 (50.0)14 (63.6)8 (36.4)0.035
 Not mutated22 (50.0)7 (31.8)15 (68.2)
PIK3CA status
 Mutated7 (15.9)5 (71.4)2 (28.6)0.34
 Not mutated37 (84.1)16 (43.2)21 (56.8)
  • NOTE: P < 0.05 are in bold.

  • aχ2 test, χ2 test with Yates' correction, or Fisher test if appropriate.